MyOme, a Menlo Park, CA-based medical entire genome platform evaluation firm, raised $23m in Sequence B financing.
The spherical, which introduced the full raised to over $36M, was led by Healthcare Enterprise Companions.
The corporate intends to make use of the funds to start commercialization of its medical entire genome evaluation platform expertise and medical reviews to well being methods.
Led by Premal Shah, PhD, CEO, and Matthew Rabinowitz, PhD, co-founder and chairman, MyOme is a medical entire genome evaluation platform firm permitting households to grasp their threat for inherited illnesses. It’s licensed underneath the Medical Laboratory Enchancment Amendments (CLIA).
FinSMEs
21/06/2022
